XOMA

79 articles about XOMA

• XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences

  1/4/2021

  XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:

• XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering

  12/21/2020

  XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered public offering of 984,000 shares, which includes the underwriters option to purchase additional 104,000 shares of its 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”), at an initial public offering price of $25.00 per share. The

• XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred Stock

  12/10/2020

  XOMA Corporation announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share at an initial public offering price of $25.00 per share, raising gross proceeds of $22.0 million before deducting underwriting discounts, the structuring fee and other estimated offering expenses.

• XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development

  11/16/2020

  XOMA Corporation announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab in participants with generalized myasthenia gravis.

• XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement

  11/11/2020

  XOMA Corporation announced it has earned a $1 million milestone payment from Agenus Inc. related to Merck’s advancement of MK-4830 into a Phase 2 study in patients with advanced non-small cell lung cancer previously treated with anti-programmed cell death receptor ligand 1 therapy.

• XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results

  11/5/2020

  Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 million milestone  Rezolute’s financing resulted in accelerated $1.4 million payment  Two partners presented early stage data at scientific conferences Acquired royalty interest in four lysosomal storage disorder enzymes being developed by Chiesi Group

• XOMA Earns $1.9 Million Associated with Two Partner Developments

  10/14/2020

  In an unrelated development, apartnerinitiated Phase 2 development of an undisclosed asset, which triggers $0.5 million milestone payment to XOMA

• XOMA to Present at Upcoming Investor Conferences

  9/2/2020

  XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference.  The presentation will take place on Monday, September 14, 2020, at 2:00 PM ET. Cantor Fitzgerald Virtual Global Healthcare Conference.  The presentation will take place on Tuesday, September 15, 2020, at 4:00 PM ET.  Live webcasts of each

• XOMA Reports Second Quarter 2020 Financial ResultsPartners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts

  8/6/2020

  XOMA Corporation, announced its second quarter 2020 royalty asset portfolio advancements and financial results.

• XOMA to Present at the 2020 Wedbush PacGrow Healthcare ConferenceLive video feed will be available on XOMA’s website

  8/5/2020

  XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present a Company business update at the Wedbush PacGrow Virtual Healthcare Conference 2020.

• XOMA Added to the Russell 2000® and Russell 3000® Indexes

  6/29/2020

  XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000 ® and Russell 3000 ® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 26, 2020. “We expect XOMA’s addition to these Russell indexes will enhance the Company’s visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer of XOMA.  The Russe

• XOMA Reports First Quarter 2020 Financial Results and Provides COVID-19 Business Update

  5/5/2020

  XOMA Corporation reported its first quarter 2020 financial results and provided a COVID-19 business update.

• Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement

  3/9/2020

  Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody

• XOMA to Present at the Cowen and Company 40th Annual Health Care Conference

  2/25/2020

  XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present an update about the Company’s business at the Cowen and Company 40th Annual Health Care Conference in Boston, Massachusetts.

• XOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

  11/5/2019

  XOMA Corporation reported its third quarter 2019 financial results.

• Agenus Closes $15 Million Partial Royalty Monetization With XOMA

  9/21/2018

  Agenus Inc. cancer vaccines, and adoptive cell therapies1, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation

• 

  Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs

  1/26/2018

  The company burned through $1.2B and never brought a drug to market in its 37 years.
• 

  3 Biopharmas Worth Watching in 2018

  1/15/2018

  Here are three biopharma stocks worth keeping an eye on.

• XOMA Strengthens Leadership Team With Appointments of Chief Business Officer and General Counsel

  1/8/2018

  Dr. Datta and Mr. Hart will report to XOMA’s Chief Executive Officer, Jim Neal.

• 

  Top 6 Biotech Stocks of 2017

  12/20/2017

  When considering options in the biotech sector, experts often look more into the major companies providing massive amounts of resources to new candidates.